DRUG DELIVERY DEVICE MARKET ANALYSIS

Drug Delivery Device Market, By Route of Administration (Oral, Parenteral, Transdermal, Ocular, Pulmonary), By Application (Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders), By End User (Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In April 2024, Bespak completed its spin-out from Recipharm, forming a new standalone company specializing in drug-device combination products and drug delivery devices for pulmonary and nasal inhalation. CEO Chris Hirst stated that the new Bespak aims to be a trusted innovation partner and sustainability leader in the shift towards greener inhalers.
In November 2023, Hovione, a leading CDMO in spray drying and particle engineering, expanded its nasal drug delivery capabilities by introducing a new range of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal delivery offers a simple, safe, and fast-acting alternative to conventional routes, with growing potential for delivering drugs to the brain for treating central nervous system (CNS) diseases.
In June 2022, Gufic Biosciences Ltd introduced a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India
In February 2022, Takeda received the U.S. FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). It is designed to prevent hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and older.